Drug pricing

News

US policy changes designed to curb drug prices seem ineffective, as the annual cost of new medicines still exceeds $250,000, curbing patient access.

Market Access

Operational review meeting minutes released by the DHSC reveal industry and government are planning to move to a 7-year agreement.

Market Access

Just over a year has passed since the Trump administration sent letters to 17 leading manufacturers demanding steps towards MFN pricing.

News

PhRMA is challenging the Trump administration's GLOBE model for Most-Favoured Nation pricing in Medicare Part B in a US district court.

News

CMS has finalised a new drug pricing policy for Medicare that has drawn sharp criticism from the pharma industry.

News

Former Republican lawmaker Eric Cantor has been named as the new CEO of US pharma group PhRMA, replacing long-serving Stephen Ubl.